Organogenesis (ORGO) Projected to Post Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will likely be issuing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $134.10 million for the quarter. Organogenesis has set its FY 2025 guidance at EPS.Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). The company had revenue of $101.01 million for the quarter, compared to analyst estimates of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Trading Down 5.9%

NASDAQ ORGO opened at $4.00 on Tuesday. The stock’s 50 day moving average is $4.48 and its two-hundred day moving average is $4.19. The company has a market capitalization of $507.44 million, a price-to-earnings ratio of -28.57 and a beta of 1.68. Organogenesis has a 1-year low of $2.61 and a 1-year high of $6.71.

Institutional Trading of Organogenesis

Large investors have recently made changes to their positions in the company. State of Wyoming bought a new stake in shares of Organogenesis in the 2nd quarter valued at $319,000. Mink Brook Asset Management LLC bought a new stake in shares of Organogenesis in the 2nd quarter valued at $340,000. First Light Asset Management LLC bought a new stake in shares of Organogenesis in the 2nd quarter valued at $24,804,000. Raymond James Financial Inc. increased its position in shares of Organogenesis by 5.7% in the 2nd quarter. Raymond James Financial Inc. now owns 444,240 shares of the company’s stock valued at $1,626,000 after buying an additional 23,919 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Organogenesis by 36.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 168,152 shares of the company’s stock valued at $617,000 after buying an additional 45,021 shares in the last quarter. Institutional investors own 49.57% of the company’s stock.

Wall Street Analyst Weigh In

ORGO has been the topic of several recent analyst reports. Cantor Fitzgerald boosted their target price on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of Organogenesis in a report on Friday, September 26th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Organogenesis currently has an average rating of “Hold” and a consensus target price of $7.33.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.